MiniMed Group (NASDAQ:MMED) Research Coverage Started at Evercore

by · The Markets Daily

Evercore assumed coverage on shares of MiniMed Group (NASDAQ:MMED – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $20.00 target price on the stock.

Other equities analysts also recently issued research reports about the stock. Morgan Stanley began coverage on shares of MiniMed Group in a research note on Tuesday. They issued an “overweight” rating and a $19.00 price objective for the company. Citigroup assumed coverage on shares of MiniMed Group in a report on Tuesday. They set a “buy” rating and a $23.00 price target for the company. Bank of America began coverage on MiniMed Group in a research note on Tuesday. They issued a “buy” rating and a $27.00 price target for the company. Piper Sandler assumed coverage on MiniMed Group in a report on Tuesday. They set a “neutral” rating and a $16.00 price objective on the stock. Finally, Mizuho started coverage on MiniMed Group in a report on Tuesday. They issued an “outperform” rating and a $21.00 target price for the company. Eleven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.45.

Get Our Latest Analysis on MiniMed Group

MiniMed Group Price Performance

MMED opened at $14.01 on Tuesday. MiniMed Group has a 1-year low of $13.52 and a 1-year high of $20.48.

MiniMed Group News Summary

Here are the key news stories impacting MiniMed Group this week:

  • Positive Sentiment: Barclays set an “overweight” rating with a $26 price target (~85% upside vs. current price), giving a clear bullish analyst catalyst. Article Title
  • Neutral Sentiment: Goldman Sachs initiated coverage on MMED (coverage note published; no widely reported price target in the release). Article Title
  • Neutral Sentiment: William Blair began coverage on MMED (initial research coverage announced). Article Title
  • Neutral Sentiment: Evercore initiated coverage on MMED (coverage note released). Article Title
  • Neutral Sentiment: Wells Fargo initiated coverage on MMED. Article Title
  • Neutral Sentiment: Piper Sandler initiated coverage on MMED. Article Title
  • Neutral Sentiment: Deutsche Bank began coverage on MMED. Article Title
  • Neutral Sentiment: Citigroup initiated coverage on MMED. Article Title
  • Neutral Sentiment: BTIG Research initiated coverage on MMED. Article Title
  • Neutral Sentiment: Mizuho began coverage on MMED. Article Title
  • Neutral Sentiment: Morgan Stanley began coverage on MMED. Article Title
  • Neutral Sentiment: Bank of America initiated coverage on MMED. Article Title

MiniMed Group Company Profile

(Get Free Report)

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.

Read More